eligibility_summary
Eligible: ≥18, CD20+ mature B‑cell lymphoma (DLBCL/HGBCL/PMBCL/FL/MCL/SLL/MZL). Escalation: R/R after anti‑CD20, Expansion: ≥2 prior lines (FL, LBCL cohorts). Need measurable disease, ECOG 0–2, adequate organs, LVEF ≥50%, life expectancy >3 mo. Exclude: prior same‑class bispecific, transplant‑eligible, CNS lymphoma, select other cancers, major cardiac/lung disease, autoimmune needing immunosuppression, seizure/PML, active infection (HIV/HBV/HCV), recent CAR‑T/HSCT/surgery/therapy/live vaccines, pregnancy, contraception required.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial: Phase Ia/Ib first-in-human study of SCTB35 in relapsed/refractory CD20+ B‑cell non-Hodgkin lymphoma. Intervention: SCTB35, a subcutaneously administered bispecific antibody (immunotherapy) given as monotherapy. Mechanism of action: bispecific antibodies are designed to bind a tumor antigen and an immune-effector target to redirect immune killing, in this trial SCTB35 targets CD20 on malignant B cells and an additional effector target not specified in the record, enabling immune synapse formation and cytotoxicity. Cells/pathways targeted: CD20-positive mature B cells across DLBCL, HGBCL, PMBCL, FL, MCL, SLL, and MZL, activation of immune effector pathways (e.g., T/NK cell–mediated killing) resulting in B‑cell depletion.